news
Therapeutic gel shows promise against cancerous tumours
Researchers have developed a biodegradable hydrogel scaffold system to release chemotherapeutic and immunotherapeutic drugs at the tumour site...
List view / Grid view
Immunotherapy
news
FDA expands approval of Imfinzi to reduce the risk of NSCLC progression
The FDA has approved Imfinzi for the treatment of patients with stage III non-small cell lung cancer whose tumours are not able to be surgically removed and whose cancer has not progressed after treatment...
news
Rare melanoma type highly responsive to immunotherapy
Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
news
NICE recommends routine access to beta interferon drug for MS
Multiple sclerosis patients to have routine access to beta interferon drug, says NICE in new draft guidance.
news
Abatacept improves survival in patients with acute GvHD
A drug used to treat rheumatoid arthritis improves survival after hematopoietic stem cell transplant...
news
A risk factor for drug-induced skin disease identified
Researchers have identified a type of human leukocyte antigen (HLA) that is associated with the skin disease bullous pemphigoid (BP) in diabetic patients administered with DPP-4 inhibitory drugs.
news
FDA-approved drug may block resistance to anti-angiogenesis therapy
General study identifies targetable pathway that induces immunosuppressive environment in colorectal cancer...
whitepaper
Application note: Quantitative Analysis of Immunosuppressant Drugs in Serum Using a QSight 110 Triple Quadrupole Mass Spectrometer
This application note describes a sensitive, fast and accurate LC/MS/MS quantitation method utilising a QSight™ 110 Triple Quadrupole Mass Spectrometer for the simultaneous analysis of the immunosuppressant drugs tacrolimus, sirolimus and cyclosporine A in serum, using everolimus as an internal standard...
news
Immunotherapy combination effective at killing cancer cells
Researchers have recently discovered an immunotherapy that uses existing cancer drugs in a whole new way...
news
Uncovering the cause of immunotherapy resistance in tumours
Scientists have uncovered a key factor in the development of immunotherapy resistance in the case of cutaneous melanoma. This could potentially lead to future improvements in cancer therapy.
news
Sandoz receives EU approval for Erelzi (biosimilar etanercept)
The European Commission (EC) has approved Sandoz’ (a Novartis division) Erelzi (biosimilar etanercept) for use in Europe, to treat inflammatory diseases...
news
Collaboration is ‘game changer’ in delivering cell and gene therapies
Collaboration between the pharmaceutical industry, patients and health regulators will be a ‘game changer’ in delivering exciting new cell and gene therapies to treat conditions like cancer and vision loss.
news
Roche receives FDA approval for bladder cancer biomarker assay
5 May 2017 | By Niamh Marriott, Junior Editor
The FDA has approved Roche’s biomarker assay as a complementary diagnostic to provide PD-L1 status for patients with urothelial carcinoma...
article
How Panacea is paving the way for vaccine immunotherapies
29 March 2017 | By Niamh Marriott, Junior Editor
We caught up with the CEO & CSO of Panacea for the latest on vaccine immunotherapies - "As a scientist, as long as you are observant and persistent, you may come up with breakthrough discoveries"
news
Immunotherapy treatment fast-tracked under UK’s access to medicines scheme
2 February 2017 | By Niamh Marriott, Digital Editor
From today, UK patients with an incurable form of bladder cancer can access the new immunotherapy, atezolizumab, following a positive Scientific Opinion...
